웰마커바이오
23 known investors
Korean biotech developing first-in-class targeted and immuno-oncology drugs guided by treatment-response predictive biomarkers.
Also known as Wellmarker Bio Co., LTD. · wmbio · 웰마커바이오 주식회사
Investors · 23
Also in the syndicate · 22
Company profile
researched Aug 2026웰마커바이오 (Wellmarker Bio Co., Ltd.) is a Korean drug developer working on anticancer therapeutics selected and matched to patients using treatment-response predictive biomarkers. The company was established in December 2016 as the first spin-off from Seoul Asan Medical Center (서울아산병원) by 진동훈, formerly a professor at the University of Ulsan College of Medicine and the inaugural head of Asan Medical Center's new drug development center. The corporate name combines "well" and "biomarker." Its registered business scope covers cancer therapeutic R&D, wholesale/retail of cosmetics and chemicals, and management consulting; headquarters are in Munjeong-dong, Songpa-gu, Seoul.
The pipeline consists of small-molecule and antibody programs against first-in-class targets, paired with biomarker research intended to predict drug responsiveness. Indications addressed include colorectal, lung, prostate and liver cancer. As of 2018 the company described five targeted oncology projects; by 2021-2022 it reported nine anticancer pipeline programs. The lead colorectal cancer program (WM-S1 / WM-S1-030), aimed at Erbitux (cetuximab)-resistant colorectal cancer patients, entered Phase 1a in February 2021, with Australian Phase 1 approval reported in February of that year. A lung cancer immuno-oncology antibody (WM-A1) was in preclinical stage as of December 2021, with cell line construction for preclinical and clinical supply carried out at Samsung Biologics, and a liver cancer program (WM-P1) was in lead optimization. The Erbitux-resistant colorectal program and a novel-mechanism immune antibody program were carried out under Korea Drug Development Fund (범부처신약개발사업단) projects.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 11
launches, deals, and filingsReceived 'A, BBB' grades in the KOSDAQ technology assessment, targeting a listing the following year.
Series C with Cytogen as strategic investor and financial investors including Magellan Technology Investment, Lead Compass Investment, T&C Asset Management, eBest Investment & Securities, G2G Private Equity and Seoul Investment Partners.
KRW 18 billion round with Cytogen as strategic investor and HB Investment, NH Investment & Securities, Sun&Tree Fund, Brick Investment, Orbit Partners and Mirae Asset Venture Investment as financial investors; proceeds earmarked for domestic and overseas trials of the colorectal cancer drug, immuno-oncology R&D for lung cancer and additional pipeline.
Business agreements reported with Biogenetics, the Korea Institute of Radiological & Medical Sciences and Vinnytsia National Medical University in Ukraine to accelerate anticancer drug R&D.
Codi M, which had co-invested to establish the company and acquired 60,000 shares for KRW 3.0 billion, sold its entire holding; press reported the company's valuation at KRW 87.5 billion.
Company announced a Series A round of KRW 28 billion from VCs, securities firms and asset managers, to be used for preclinical work, clinical development and pipeline expansion.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- 웰마커바이오 - 위키백과, 우리 모두의 백과사전ko.wikipedia.org · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 웰마커바이오 do?
- Korean biotech developing first-in-class targeted and immuno-oncology drugs guided by treatment-response predictive biomarkers.
- Who are 웰마커바이오's investors?
- 웰마커바이오's investors include Laguna Investment.